Currently, Dr. Stein serves as the chief medical officer and executive vice president at the biopharmaceutical company Incyte. Prior to this role, Dr. Stein held leadership roles at Novartis Pharmaceuticals Corp., according to an Oct. 19 Theseus news release.
“We are delighted to welcome Dr. Stein to the Theseus Board as we advance development of our THE-630 and THE-349 programs, while also expanding our early-stage pipeline,” Tim Clackson, PhD, president and CEO of Theseus, said in the news release. “Dr. Stein’s depth and breadth of oncology expertise, and extensive track record of bringing effective medicines through development and to patients, will be invaluable as we continue to build Theseus as a leading precision oncology company.”
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.